IN2014MN00933A - - Google Patents
Info
- Publication number
- IN2014MN00933A IN2014MN00933A IN933MUN2014A IN2014MN00933A IN 2014MN00933 A IN2014MN00933 A IN 2014MN00933A IN 933MUN2014 A IN933MUN2014 A IN 933MUN2014A IN 2014MN00933 A IN2014MN00933 A IN 2014MN00933A
- Authority
- IN
- India
- Prior art keywords
- insulin analogue
- therapeutic agent
- present
- provides
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110422095 | 2011-12-15 | ||
| PCT/CN2012/085054 WO2013086927A1 (fr) | 2011-12-15 | 2012-11-22 | Analogue d'insuline humaine et son dérivé acylé |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN00933A true IN2014MN00933A (fr) | 2015-05-01 |
Family
ID=48611849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN933MUN2014 IN2014MN00933A (fr) | 2011-12-15 | 2012-11-22 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9458219B2 (fr) |
| EP (1) | EP2784085A4 (fr) |
| JP (1) | JP6153206B2 (fr) |
| KR (1) | KR20140104994A (fr) |
| CN (2) | CN104788556A (fr) |
| AU (1) | AU2012350586B2 (fr) |
| BR (1) | BR112014013483A2 (fr) |
| CA (1) | CA2858253A1 (fr) |
| HK (1) | HK1188795A1 (fr) |
| IN (1) | IN2014MN00933A (fr) |
| MX (1) | MX2014006698A (fr) |
| RU (1) | RU2014127270A (fr) |
| TW (1) | TW201323439A (fr) |
| WO (1) | WO2013086927A1 (fr) |
| ZA (1) | ZA201404417B (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016311283B2 (en) | 2015-08-25 | 2020-10-08 | Novo Nordisk A/S | Novel insulin derivatives and the medical uses hereof |
| CN106496322A (zh) * | 2015-09-07 | 2017-03-15 | 江苏恒瑞医药股份有限公司 | 人胰岛素或其类似物的酰化衍生物的制备方法 |
| CN105491227A (zh) * | 2015-11-20 | 2016-04-13 | 努比亚技术有限公司 | 一种消息排列方法和终端 |
| EP3260548A1 (fr) | 2016-06-21 | 2017-12-27 | Enzypep B.V. | Couplage enzymatique d'(oligo)peptides pour la chaîne b d'un ligand du récepteur de l'insuline |
| CN108463468B (zh) * | 2016-08-02 | 2022-03-04 | 江苏恒瑞医药股份有限公司 | 一种人胰岛素或其类似物的酰化衍生物 |
| US20210040171A1 (en) * | 2018-02-01 | 2021-02-11 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition comprising acylated derivative of human insulin analog and preparation method thereof |
| RU2020128190A (ru) * | 2018-02-09 | 2022-03-09 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Кодон-оптимизированный ген предшественника и ген сигнального пептида аналога человеческого инсулина |
| CA3122637A1 (fr) | 2018-12-11 | 2020-06-18 | Sanofi | Liant peptidique |
| CN111909255A (zh) * | 2019-05-10 | 2020-11-10 | 宁波鲲鹏生物科技有限公司 | 胰岛素衍生物及其制备方法 |
| EP4073097A1 (fr) | 2019-12-11 | 2022-10-19 | Novo Nordisk A/S | Nouveaux analogues de l'insuline et leurs utilisations |
| KR20220121833A (ko) | 2019-12-30 | 2022-09-01 | 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 | 인슐린 유도체 |
| CN113773398B (zh) * | 2020-06-10 | 2023-05-23 | 宁波鲲鹏生物科技有限公司 | 一种德谷胰岛素衍生物及其应用 |
| EP4347632A1 (fr) * | 2021-05-24 | 2024-04-10 | Sunshine Lake Pharma Co., Ltd. | Nouvel analogue d'insuline acylé |
| AU2022300061A1 (en) | 2021-06-25 | 2024-02-01 | Gan & Lee Pharmaceuticals Co., Ltd. | Acylated insulin-containing pharmaceutical composition |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5008241A (en) | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
| PH25772A (en) * | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
| ATE93238T1 (de) | 1988-07-20 | 1993-09-15 | Novo Nordisk As | Menschliche insulinanalage und zubereitungen daraus. |
| JPH04502465A (ja) | 1988-12-23 | 1992-05-07 | ノボ ノルディスク アクティーゼルスカブ | ヒトインシュリン類似物質 |
| JP3014764B2 (ja) * | 1993-09-17 | 2000-02-28 | ノボ ノルディスク アクティーゼルスカブ | アシル化インスリン |
| CN1195777A (zh) | 1997-05-28 | 1998-10-14 | 姚维明 | 电力拖动实验仪 |
| JP4773023B2 (ja) * | 1999-12-29 | 2011-09-14 | ノボ ノルディスク アクティーゼルスカブ | インスリン前駆体及びインスリン前駆体類似体の製造方法 |
| US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US6770625B2 (en) * | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| US7193035B2 (en) | 2002-10-29 | 2007-03-20 | Sanofi-Aventis Deutschland Gmbh | Crystals of insulin analogs and processes for their preparation |
| CN1780854A (zh) | 2003-04-29 | 2006-05-31 | 伊莱利利公司 | 具有延长时间作用的胰岛素类似物 |
| EP1660531A2 (fr) * | 2003-08-05 | 2006-05-31 | Novo Nordisk A/S | Nouveaux derives de l'insuline |
| PT2275439E (pt) * | 2003-08-05 | 2014-06-25 | Novo Nordisk As | Novos derivados de insulina |
| CN101721712A (zh) * | 2008-10-21 | 2010-06-09 | 何明磊 | 一种双链聚乙二醇－胰岛素复合物及其制备方法 |
-
2012
- 2012-11-22 WO PCT/CN2012/085054 patent/WO2013086927A1/fr active Application Filing
- 2012-11-22 RU RU2014127270A patent/RU2014127270A/ru not_active Application Discontinuation
- 2012-11-22 CA CA2858253A patent/CA2858253A1/fr not_active Abandoned
- 2012-11-22 US US14/363,328 patent/US9458219B2/en not_active Expired - Fee Related
- 2012-11-22 KR KR1020147018616A patent/KR20140104994A/ko not_active Application Discontinuation
- 2012-11-22 BR BR112014013483A patent/BR112014013483A2/pt not_active IP Right Cessation
- 2012-11-22 CN CN201510174792.9A patent/CN104788556A/zh active Pending
- 2012-11-22 CN CN201280011736.8A patent/CN103443122B/zh active Active
- 2012-11-22 AU AU2012350586A patent/AU2012350586B2/en not_active Ceased
- 2012-11-22 JP JP2014546293A patent/JP6153206B2/ja not_active Expired - Fee Related
- 2012-11-22 EP EP12857862.2A patent/EP2784085A4/fr not_active Withdrawn
- 2012-11-22 IN IN933MUN2014 patent/IN2014MN00933A/en unknown
- 2012-11-22 MX MX2014006698A patent/MX2014006698A/es unknown
- 2012-11-30 TW TW101144976A patent/TW201323439A/zh unknown
-
2014
- 2014-02-26 HK HK14101852.9A patent/HK1188795A1/zh not_active IP Right Cessation
- 2014-06-17 ZA ZA2014/04417A patent/ZA201404417B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014013483A2 (pt) | 2019-09-24 |
| CN104788556A (zh) | 2015-07-22 |
| CN103443122A (zh) | 2013-12-11 |
| EP2784085A4 (fr) | 2015-07-08 |
| US20140329745A1 (en) | 2014-11-06 |
| US9458219B2 (en) | 2016-10-04 |
| ZA201404417B (en) | 2016-07-27 |
| AU2012350586B2 (en) | 2017-02-02 |
| TW201323439A (zh) | 2013-06-16 |
| RU2014127270A (ru) | 2016-02-10 |
| MX2014006698A (es) | 2014-07-09 |
| KR20140104994A (ko) | 2014-08-29 |
| EP2784085A1 (fr) | 2014-10-01 |
| AU2012350586A1 (en) | 2014-07-03 |
| HK1188795A1 (zh) | 2014-05-16 |
| JP6153206B2 (ja) | 2017-06-28 |
| CA2858253A1 (fr) | 2013-06-20 |
| CN103443122B (zh) | 2016-05-11 |
| JP2015501819A (ja) | 2015-01-19 |
| WO2013086927A1 (fr) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN00933A (fr) | ||
| ZA201505849B (en) | Composition of novel carbohydrate drug for treatment of human diseases | |
| PH12016500606A1 (en) | Insulin preparations containing methionine | |
| PL2547323T3 (pl) | Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego | |
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| IL216399A0 (en) | Pharmaceutical composition for the treatment of heart diseases | |
| EA201390796A1 (ru) | Применение ацилированного аналога глюкагона | |
| AP3155A (en) | Methods of administering pirfenidone therapy | |
| MX349004B (es) | Nuevos compuestos. | |
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| EP2782631A4 (fr) | Appareil implantable utilisable en vue de l'administration d'un médicament solide-liquide, formulations associées et procédés d'utilisation | |
| PH12014501258A1 (en) | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof | |
| NZ701607A (en) | Therapeutic use of chardonnay seed products | |
| ZA201304822B (en) | Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases | |
| IL254446A0 (en) | Implantable drug delivery preparations and treatment methods thereof | |
| WO2012071369A3 (fr) | Antagoniste rbp4 non rétinoïde pour le traitement de la dégénérescence maculaire liée à l'âge et de la maladie de stargardt | |
| EP2623494A4 (fr) | Agent pour le traitement de maladies oculaires | |
| WO2014160281A3 (fr) | Procédé pour améliorer l'administration de composés thérapeutiques à l'œil | |
| AU2010286532A8 (en) | Methods of treatment using anti-oxidized LDL antibodies | |
| IN2014DN03010A (fr) | ||
| WO2012123519A3 (fr) | Analogues de l'insuline humaine et dérivés comprenant des substitutions de cystéine | |
| EP2402342A4 (fr) | Composition pharmaceutique servant a traiter le diabete de type 2 | |
| WO2011026193A8 (fr) | Composés cytotoxiques | |
| UA42333U (uk) | Спосіб лікування алергічних захворювань | |
| HUP1100723A2 (en) | Use of estrogen derivatives for preparing medicament for the treatment of psychiatric diseases |